HUMAN DIPLOID CELL RABIES VACCINE

A vaccine developed to provide immunity against rabies, a deadly viral infection transmitted through the bite of a rabid animal. The vaccine is produced using human diploid cells and is highly effective in preventing the onset of rabies when administered properly.

Indications

-Prevention of rabies in individuals exposed to potential rabies-infected animals. -Post-exposure prophylaxis (PEP) for people who have been bitten or scratched by a potentially rabid animal.

Dosage

-Pre-exposure Prophylaxis: Typically administered as a series of three doses (0.5 mL each) at days 0, 7, and 21 or 28. -Post-exposure Prophylaxis: Administered as a series of four doses (1.0 mL each) on days 0, 3, 7, and 14. If previously vaccinated, a reduced schedule may be used.

Contra-Indications

-Known hypersensitivity to any component of the vaccine. -Severe allergic reactions to previous doses of the rabies vaccine.

Special Precautions

-Should be used with caution in individuals with compromised immune systems. -Monitor for allergic reactions after administration. -Consult with a healthcare provider for individuals with a history of neurological disorders.

Side Effects

-Common: Pain, redness, or swelling at the injection site. -Rare: Fever, headache, dizziness, allergic reactions, or systemic reactions.